274693-25-3

Usage

Uses

Used in Pharmaceutical Industry:
2-[[(3aR,4S,6R,6aS)-6-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-acetic acid methyl ester is used as a precursor in the synthesis of pharmacologically active compounds for various therapeutic applications. Its unique structure, including the 1,2,3-triazole and pyrimidine moieties, allows for specific interactions with biological targets, making it a valuable component in the development of new drugs.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-[[(3aR,4S,6R,6aS)-6-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-acetic acid methyl ester serves as a key intermediate in the design and synthesis of novel bioactive molecules. Its complex structure and functional groups provide a foundation for further modification and optimization to enhance its pharmacological properties and therapeutic potential.

Upstream product

• 220241-60-1 (3aR,4S,6R,6aS)-6-((5-amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 220241-61-2 (3aR,4S,6R,6aS)-6-(7-chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 1431867-41-2 (3aR,4S,6R,6aS)-6-((6-methoxy-5-nitro-2-(propylthio)pyrimidin-4-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 1431867-42-3 (3aR,4S,6R,6aS)-6-((5-amino-6-methoxy-2-(propylthio)pyrimidin-4-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 1431867-43-4 (3aR,4S,6R,6aS)-6-(7-methoxy-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 145783-14-8 4,6-dichloro-5-nitro-2-(propylsulfanyl)pyrimidine 
• 145783-15-9 4,6-dichloro-2-(propylsulfanyl)-5-pyrimidinamine 
• 220241-59-8 (3aR,4S,6R,6aS)-6-((6-chloro-5-nitro-2-(propylthio)pyrimidin-4-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 1402150-26-8 ((3aR,4S,6R,6aS)-(6-(((benzyloxy)carbonyl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d](1,3)dioxol-4-yl)oxy)acetic acid 
• 1402150-27-9 ((3aR,4S,6R,6aS)-(6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d](1,3)dioxol-4-yl)oxy)acetic acid 
• 145783-13-7 4,6-dihydroxy-5-nitro-2-(propylthio)pyrimidine 
• 1402222-66-5 trans-(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine hydrochloride 
• 274693-53-7 [3aS-(3aα,4α,6α,6aα)]-(tetrahydro-6-hydroxy-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl)carbamic acid phenylmethyl ester 
• 1431867-39-8 4-chloro-6-methoxy-5-nitro-2-(propylthio)pyrimidine 

Downstream Products

• 274693-26-4 [3aR-[3aα,4α,6α,(1R,2S),6aα]]-2-[6-[[[7-(2-(3,4-difluorophenyl)cyclopropyl)]amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-4H-cyclopenteno-1,3-dioxolan-4-yl]oxy]ethanol 
• 274693-27-5 ticagrelor 

Relevant academic research and scientific papers

PROCESSES FOR THE PREPARATION OF TICAGRELOR AND ITS INTERMEDIATES

The present invention provides a process for the preparation of ticagrelor. The present invention further provides compounds of Formula IV, Formula V, Formula VI, Formula VIa, Formula VII, and Formula VIII, processes for their preparation, and their use for the preparation of ticagrelor.

Synthesis of Triazolopyrimidine Compounds

The present invention relates to the field of organic synthesis and describes the synthesis of specific triazolopyrimidine compounds and intermediates thereof as well as related derivatives.

SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS

The present invention relates to the field of organic synthesis and describes the synthesis of specific triazolopyrimidine compounds and intermediates thereof as well as related derivatives.

Triazolo(4,5-d)pyrimidine compounds

Triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows: wherein R, X and R1through R3are as defined in the specification.

Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound

The invention provides new forms of a chemical compound of formula (I). The invention relates to forms fo a chemical compound (I), in particular to crystalline and amorphous forms, more particularly four crystalline forms and an amorphous form. The invention further relates to processes for the preparation of such forms, to pharmaceutical compositions comprising the compound in crystalline and/or amorphous form and to therapeutic use of such forms.